10q10k10q10k.net
Galecto, Inc.

Galecto, Inc.GLTOEarnings & Financial Report

Nasdaq

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.

NextMar 19, 2026

GLTO Q3 2025 Key Financial Metrics

Revenue

$42.0K

Gross Profit

N/A

Operating Profit

$-3.2M

Net Profit

$-3.1M

Gross Margin

N/A

Operating Margin

-7514.3%

Net Margin

-7459.5%

YoY Growth

-71.2%

EPS

$-2.36

Financial Flow

Galecto, Inc. Q3 2025 Financial Summary

Galecto, Inc. reported revenue of $42.0K for Q3 2025, with a net profit of $-3.1M (-7459.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$42.0K
Net Profit$-3.1M
Gross MarginN/A
Operating Margin-7514.3%
Report PeriodQ3 2025

Galecto, Inc. Annual Revenue by Year

Galecto, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $844.0K).

YearAnnual Revenue
2024$844.0K
2023$1.7M
2022$722.0K

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$340000$257000$213000$146000$228000$74000$50000$42000
YoY Growth19.7%-40.8%-51.8%-69.1%-32.9%-71.2%-76.5%-71.2%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$38.2M$32.5M$27.3M$23.4M$17.1M$15.4M$13.7M$10.7M
Liabilities$5.9M$4.3M$3.7M$2.4M$1.3M$1.7M$2.7M$2.7M
Equity$32.3M$28.2M$23.6M$20.9M$15.8M$13.7M$11.0M$8.0M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-11.5M$-5.9M$-4.1M$-3.7M$-4.9M$-2.4M$-2.2M$-2.6M